Compare LLY & JPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LLY | JPM |
|---|---|---|
| Founded | 1876 | 1799 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.5B | 823.1B |
| IPO Year | N/A | N/A |
| Metric | LLY | JPM |
|---|---|---|
| Price | $1,008.13 | $315.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 13 |
| Target Price | ★ $1,063.44 | $326.08 |
| AVG Volume (30 Days) | 3.9M | ★ 7.8M |
| Earning Date | 10-30-2025 | 01-14-2026 |
| Dividend Yield | 0.59% | ★ 1.90% |
| EPS Growth | ★ 121.02 | 12.35 |
| EPS | ★ 20.44 | 20.18 |
| Revenue | $59,419,800,000.00 | ★ $167,229,000,000.00 |
| Revenue This Year | $42.59 | $11.41 |
| Revenue Next Year | $19.62 | $3.42 |
| P/E Ratio | $49.42 | ★ $15.61 |
| Revenue Growth | ★ 45.41 | 3.13 |
| 52 Week Low | $623.78 | $202.16 |
| 52 Week High | $1,111.99 | $322.25 |
| Indicator | LLY | JPM |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 58.52 |
| Support Level | $1,038.00 | $306.80 |
| Resistance Level | $1,111.99 | $318.49 |
| Average True Range (ATR) | 27.26 | 6.31 |
| MACD | -13.38 | 1.21 |
| Stochastic Oscillator | 8.00 | 85.71 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with more than $4 trillion in assets. It is organized into four major segments: consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates and is subject to regulation in multiple countries.